Zynerba Pharmaceuticals

zynerba.com

Zynerba (NASDAQ: ZYNE) is dedicated to improving the lives of people with rare and near rare neuropsychiatric disorders where there is a high unmet medical need by pioneering the development and commercialization of next-generation pharmaceutically-produced cannabinoid therapeutics formulated for transdermal delivery. Cannabinoids interact with specific receptors throughout the body to produce pharmacologic effects, primarily in the CNS and immune systems. Transdermal delivery has the potential to reduce adverse effects associated with oral dosing because it allows the drug to be absorbed through the skin directly into the bloodstream, avoiding the gastrointestinal tract and lessening the opportunity for GI-related adverse events. It also avoids first-pass liver metabolism, potentially enabling lower dosage levels of active pharmaceutical ingredients with a higher bioavailability and an improved safety profile. Zynerba’s lead patent-protected product candidate in clinical development is ZYN002: ZYN002 is the first and only pharmaceutically-produced cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BUSINESS INSIGHTS

AQUESTIVE THERAPEUTICS RECEIVES FDA TENTATIVE APPROVAL FOR LIBERVANT™ (DIAZEPAM) BUCCAL FILM

Aquestive Therapeutics, Inc. | August 31, 2022

news image

Aquestive Therapeutics, Inc. a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced today that the U.S. Food & Drug Administration has granted tentative approval for Libervant™ Buccal Film for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity that are distinct from a patient’s usual seizure pattern in patients with epileps...

Read More

BUSINESS INSIGHTS, PHARMA TECH

KSQ ANNOUNCES ONO’S ACQUISITION OF MULTIPLE RESEARCH-STAGE ONCOLOGY PROGRAMS

KSQ Therapeutics | January 30, 2023

news image

KSQ Therapeutics, a leading clinical-stage biotechnology company developing therapies to treat cancer and autoimmune diseases, recently announced that Ono Pharmaceutical (ONO) has acquired multiple research-stage DNA damage response (DDR) programs. The programs were identified using KSQ's CRISPRomics platform technology. All of the programs are new and have the potential to be first-in-class therapies. ONO's Discovery & Research Executive Director/ Senior Executive O...

Read More

BUSINESS INSIGHTS

WITH VEEVA ECONSENT, CELERION IS CHANGING THE CONSENT EXPERIENCE FOR CLINICS AND PATIENTS

Veeva Systems | October 07, 2021

news image

Veeva Systems (NYSE: VEEV ) announced that Celerion has launched Veeva eConsent , a MyVeeva for Patients solution, to provide electronic consent for its Phase I clinical trials obtain. With Veeva eConsent, Celerion is moving from manual and paper-based consent forms to a fully digital process. The company uses Veeva eConsent for several studies and has already given their consent to more than 200 test subjects. Covid-19 limited the time we cou...

Read More

BUSINESS INSIGHTS

LOVE PHARMAS INVESTMENT IN US BIOTECH OFFERS STRATEGIC INDUSTRY ADVANTAGES AND ENHANCED SHAREHOLDER VALUE

LOVE Pharma | September 09, 2022

news image

Love Pharma Inc. an international mental health and sexual wellness company, remains extremely active in shaping itself into a real competitor in the biotech/pharmaceutical space. The company’s growth and development plan took a major leap forward this week with the announcement that Love Pharma is establishing a “strategic alliance” with Starton Therapeutics a leading clinical-stage biotechnology company in the United States. It’s a relationship that...

Read More
news image

BUSINESS INSIGHTS

AQUESTIVE THERAPEUTICS RECEIVES FDA TENTATIVE APPROVAL FOR LIBERVANT™ (DIAZEPAM) BUCCAL FILM

Aquestive Therapeutics, Inc. | August 31, 2022

Aquestive Therapeutics, Inc. a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced today that the U.S. Food & Drug Administration has granted tentative approval for Libervant™ Buccal Film for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity that are distinct from a patient’s usual seizure pattern in patients with epileps...

Read More
news image

BUSINESS INSIGHTS, PHARMA TECH

KSQ ANNOUNCES ONO’S ACQUISITION OF MULTIPLE RESEARCH-STAGE ONCOLOGY PROGRAMS

KSQ Therapeutics | January 30, 2023

KSQ Therapeutics, a leading clinical-stage biotechnology company developing therapies to treat cancer and autoimmune diseases, recently announced that Ono Pharmaceutical (ONO) has acquired multiple research-stage DNA damage response (DDR) programs. The programs were identified using KSQ's CRISPRomics platform technology. All of the programs are new and have the potential to be first-in-class therapies. ONO's Discovery & Research Executive Director/ Senior Executive O...

Read More
news image

BUSINESS INSIGHTS

WITH VEEVA ECONSENT, CELERION IS CHANGING THE CONSENT EXPERIENCE FOR CLINICS AND PATIENTS

Veeva Systems | October 07, 2021

Veeva Systems (NYSE: VEEV ) announced that Celerion has launched Veeva eConsent , a MyVeeva for Patients solution, to provide electronic consent for its Phase I clinical trials obtain. With Veeva eConsent, Celerion is moving from manual and paper-based consent forms to a fully digital process. The company uses Veeva eConsent for several studies and has already given their consent to more than 200 test subjects. Covid-19 limited the time we cou...

Read More
news image

BUSINESS INSIGHTS

LOVE PHARMAS INVESTMENT IN US BIOTECH OFFERS STRATEGIC INDUSTRY ADVANTAGES AND ENHANCED SHAREHOLDER VALUE

LOVE Pharma | September 09, 2022

Love Pharma Inc. an international mental health and sexual wellness company, remains extremely active in shaping itself into a real competitor in the biotech/pharmaceutical space. The company’s growth and development plan took a major leap forward this week with the announcement that Love Pharma is establishing a “strategic alliance” with Starton Therapeutics a leading clinical-stage biotechnology company in the United States. It’s a relationship that...

Read More

Resources

resource image

BUSINESS INSIGHTS, PHARMACY MARKET

Welcome to the Azelis Pharma lab in Paris, France!

Video

resource image

PHARMACY MARKET, PHARMA TECH

Pharmaceutical Industry World Economy Scenario

infographic

resource image

BUSINESS INSIGHTS

Pharmacy Management Software

Video

resource image

BUSINESS INSIGHTS, PHARMACY MARKET

Welcome to the Azelis Pharma lab in Paris, France!

Video

resource image

PHARMACY MARKET, PHARMA TECH

Pharmaceutical Industry World Economy Scenario

infographic

resource image

BUSINESS INSIGHTS

Pharmacy Management Software

Video

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us